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Exposure to estrogens during various stages of development has been shown to irreversibly influence responsive target organs. The recent finding of
the presence of estrogen receptor in both osteoblasts and osteoclasts has suggested a direct role of steroid hormones on bone tissue. Furthermore,
estrogens have important effects on bone turnover in both humans and experimental animal models. Thus, this tissue is now regarded as a specific
estrogen target tissue. To investigate whether a short-term developmental exposure to estrogens can influence bone tissue, we have injected female
mice with diethylstilbestrol (DES) from day 1 through day 5 of life. Additionally, a group of pregnant female mice were injected with different doses of
DES from day 9 through 16 of pregnancy. Mice were then weaned at 21 days of age, and effects on bone tissue of the female mice were evaluated
in adulthood (7-12 months of age). These short-term treatments did not affect body weight of exposed mice. However, a dose-dependent increase in
bone mass, both in the trabecular and compact compartments, was observed in the DES-exposed female offspring. Furthermore, femurs from DES-
exposed females were shorter than femurs from controls. A normal skeletal mineralization accompanied these changes in the bone tissue. In fact, a
parallel increase in total calcium content of the skeleton was found in concomitance with the increase in bone mass. Estrogen treatment induced an
increase in the amount of mineralized skeleton when compared to untreated controls. In summary, this report shows that alterations of estrogen lev-
els during development can influence the early phases of bone tissue development inducing permanent changes in the skeleton. These changes
appear to be related to bone cell programming in early phases of life. Environ Health Perspect 103(Suppl 7):95-97 (1995)
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Introduction
In 1948, Albright et al. (1) were the first to
suggest a strong link between the decrease
of estrogen levels and the onset of post-
menopausal osteoporosis. He had already
demonstrated how women develop a severe
osteopenia after the reduction of circulat-
ing levels of estrogens during the years fol-
lowing menopause (1). Since this first
report, many studies have focused on
assessing the role estrogens play in bone-
cell homeostasis and have demonstrated
the importance of these steroids in the
onset of postmenopausal osteoporosis
(2-6). Additionally, estrogen receptor
(ER) has been detected in bone cells, both
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osteoblasts and osteoclasts (7-9), and sev-
eral studies have shown that estrogens can
modulate bone cell physiology in vitro by a
direct ER-mediated mechanism (10-12).
This evidence implicates a direct effect of
estrogen on the skeleton and ultimately on
bone tissue turnover. Natural estrogens
such as estradiol were shown to induce
permanent changes in the skeleton ofadult
animals when given as long-term treatment
(2-5). Additionally, it has also been shown
that synthetic estrogenic compounds such
as diethylstilbestrol (DES) can also pro-
duce effects on the skeleton of both mice
and rats at adulthood (13-15). Further-
more, additional evidence has shown that
phytoestrogens, which are widely present
in our environment (16-18), seem to have
some modulatory effects on bone cells in
vitro (19) and, moreover, influence skeletal
tissue in vivo (JB Anderson et al., unpub-
lished data). Finally, exposure to the exoge-
nous estrogenic compound DES during
development can influence the growth of
estrogen target tissues and produce perma-
nent alterations still detectable in the adult
animals (20,21). To evaluate whether
changes in the estrogen levels during
development could affect skeletal tissue, a
poorly characterized estrogen target organ,
a developmental animal model, was used to
demonstrate anypotential effects.
Materials and Methods
To address the question ofwhether changes
in estrogen levels during development
could affect skeletal characteristics, we used
an animal model involving neonatal expo-
sure (20) that has been used by several
investigators to evaluate the potential effects
that alterations of environmental estrogens
could have on specific target tissues (22).
Outbred CD-1 female mice were injected
subcutaneously with DES (2 pg/pup/day)
dissolved in corn oil or vehicle only (CTL)
from days 1 through 5 after birth as previ-
ously described (22). Additionally, preg-
nant female mice were injected from day 9
through day 16 ofpregnancy with different
doses of DES in corn oil (0.1-100 pg/kg
maternal body weight) or vehicle only (S
Migliaccio and KS Korach, unpublished
observations). Offspring ofthe treated preg-
nant mice or neonatally treated mice were
then evaluated at adulthood between 7 and
14 months ofage (23).
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Results and Discussion
When animals were evaluated in adult-
hood, no changes in body weight were
found. However, when physical, biochem-
ical, and histological characteristics of
bone tissue were estimated, significant dif-
ferences were found between control and
DES-treated animals [S Migliaccio and KS
Korach, unpublished observations (22)].
In particular, transient treatment of ani-
mals with estrogens during early phases of
development, either before birth or soon
after birth, enhanced bone mass. This
increase was observed both in the cortical
and trabecular bone compartments (Figure
1), with similar characteristics observed in
animals transiently exposed to the syn-
thetic estrogenic compound either prena-
tally or neonatally. In particular, the
increase in the bone density observed in
the prenatally treated mice was dose
dependent, suggesting similarities to a
receptor-mediated effect. The similar
effects observed with both types of treat-
ment suggest that a period of sensitivity
exists during which estrogens can influence
bone tissue development.
To further investigate the mechanisms)
involved in this event and whether these
changes could be the result of different
bone cell homeostasis, analysis ofosteoclas-
tic cells was performed. Evaluation was per-
formed using the tartrate-resistant acid
phosphatase (TRAP) activity as a marker
for osteoclast activity. Our results suggest a
decrease in osteoclast number and TRAP
acivity in the animal developmentally
treated with DES (S Migliaccio and KS
Korach, unpublished observations). The
presence ofa change in the osteoclast num-
ber and TRAP activity in the bone tissue of
these adult female mice strongly suggests
that the transient treatment with estrogen
during development influnced bone cell
programming with a long-term effect
detectable in later phases of life. The
changes in the bone cell activity of these
animals seem to suggest a decrease in the
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amount ofthe bone resorption, with a final
result ofan increase in the bone mass.
At the present time our result cannot
either indicate or rule out any potential ter-
atogenic or carcinogenic effect of the early
exposure to DES in the skeleton of these
female mice. It is interesting to know,
however, that there have been a few self
reports of spondylolisthesis in women
exposed prenatally to DES (23). Thus, it
may be clinically important to further
investigate the possibility that exposure of
the human population to exogenous estro-
gens could permanently affect skeletal
tissue. In particular, it will be clinically
relevent to evaluate whether low or high
doses of these steroids could affect the
skeleton in different manner, for instance
increasing peak bone density or inducing
skeletal malformations at higher doses. In
conclusion, our results show for the first
time that developmental exposure to estro-
gens during certain stages can permanently
influence bone tissue in an animal model.
The observed changes appear to be due
to an effect on bone cell programming
since differences in bone cell number and
activity are retained through adulthood.
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